Evercore ISI began coverage on shares of Organon & Co. (NYSE:OGN) in a report published on Thursday morning, Price Targets.com reports. The brokerage issued an outperform rating on the stock.
OGN has been the topic of several other reports. The Goldman Sachs Group initiated coverage on Organon & Co. in a report on Thursday, June 3rd. They set a neutral rating and a $35.00 price target on the stock. Truist initiated coverage on Organon & Co. in a report on Wednesday, June 2nd. They set a buy rating and a $48.00 price target on the stock. Finally, Cowen initiated coverage on Organon & Co. in a report on Thursday, June 3rd. They set a market perform rating and a $40.00 price target on the stock.
NYSE OGN opened at $30.33 on Thursday. Organon & Co. has a 1-year low of $27.25 and a 1-year high of $38.75.
Organon & Co, a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.